Recruiting

Testing a personalized immune therapy for recurring ovarian cancer

Plain-English translation of NCT06366490 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called Innocell, which is a personalized vaccine created specifically for each patient using their own cancer cells. The vaccine is designed to train your immune system to recognize and fight your ovarian cancer. This is a Phase 1 study, meaning it's an early test to see if the treatment is safe and whether it helps your body's immune system respond to the cancer.

Ovarian cancer that comes back after initial chemotherapy is difficult to treat, and current options are limited. Researchers believe that using a personalized vaccine made from each patient's own tumor cells may help the immune system fight the cancer more effectively.

Do you qualify?

You likely qualify if…

you are at least 18 years old and female
you have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back or gotten worse after at least one round of platinum-based chemotherapy
you have already received standard treatments like PARP inhibitors or bevacizumab if appropriate for your cancer
you have at least two areas of cancer that can be measured or detected by imaging
your overall health and organ function (blood counts, liver, and kidney function) are acceptable for the study

You likely don't qualify if…

you have HIV, hepatitis C, hepatitis B, or HTLV-1/2
you have a weakened immune system or a current autoimmune disease that requires treatment with immunosuppressive medications
you have taken systemic steroids or other immune-suppressing medications within the past 14 days
you received live vaccines within the past 28 days or other investigational drugs within the past 4 weeks
you received systemic chemotherapy or other cancer treatment within the past 3 weeks

What participation looks like

If you join this trial, you will first have a biopsy to collect tumor tissue, which is used to create your personalized vaccine in the laboratory. Once the vaccine is ready, you will receive three injections under the skin, given two weeks apart. You'll be monitored for at least 60 minutes after each injection and have a follow-up visit two days later. Blood tests will be done before each dose and after to check your immune response and cancer burden. The entire study commitment spans several weeks, with careful tracking of any side effects for at least 30 days after your last dose.

AI-generated summary from trial data · Jun 27, 2026 · Not medical advice

Trial locations(1 site)

United States

City of Hope, Duarte, California